The functional role of dendritic cells in atherogenesis (review)

Molecular Medicine Reports

Volumn 3, Issue 4, 2010, Pages 551-554

  Puddu, Paolo ^a   Puddu, Giovanni M ^a   Cravero, Eleonora ^a   Muscari, Silvia ^a   Muscari, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherosclerosis; Dendritic cells

Indexed keywords

ATORVASTATIN; CIGLITAZONE; DILTIAZEM; FENOFIBRATE; HEAT SHOCK PROTEIN; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OXIDIZED LOW DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CELL FUNCTION; DENDRITIC CELL; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; PATHOGENESIS; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 77956670868     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000295     Document Type: Review

References (56)

1. Tedgui A and Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515-581, 2006.
2. Jawień J: New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn 118: 127-131, 2008. (Pubitemid 351488259)
3. Hansson GK: Atherosclerosis - an immune disease: the Anitschkov lecture 2007. Atherosclerosis 202: 2-10, 2009.
4. Weber C, Zernecke A and Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8: 802-815, 2008.
5. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21: 1876-1890, 2001.
6. Gown AM, Tsukada T and Ross R: Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol 125: 191-207, 1986. (Pubitemid 17183772)
7. Hansson GK, Holm J and Jonasson L: Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135: 169-175, 1989 (Pubitemid 19229001)
8. Link A and Böhm M: Potential role of dendritic cells in atherogenesis. Cardiovasc Res 55: 708-709, 2002.
9. Bobryshev YV and Lord RS: Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res 37: 799-810, 1998.
10. Ozmen J, Bobryshev YV, Lord RS and Ashwell KW: Identification of dendritic cells in aortic atherosclerotic lesions in rats with diet-induced hypercholesterolaemia. Histol Histopathol 17: 223-237, 2002. (Pubitemid 34116426)
11. Bobryshev YV, Taksir T, Lord RS and Freeman MW: Evidence that dendritic cells infiltrate atherosclerotic lesions in apolipoprotein E-deficient mice. Histol Histopathol 16: 801-808, 2001. (Pubitemid 32700390)
12. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
13. Sharma R and Li DZ: Role of dendritic cells in atherosclerosis. Asian Cardiovasc Thorac Ann 14: 166-169, 2006.
14. Mallat Z, Taleb S, Ait-Oufella H and Tedgui A: The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 50: S364-S369, 2009.
15. Lotze MT and Thomson AW (eds): Dendritic Cells: Biology and Clinical Applications. 2nd edition. Academic Press, San Diego, CA, 2001.
16. Hume DA: Macrophages as APC and the dendritic cell myth. J Immunol 181: 5829-5835, 2008.
17. Lipscomb MF and Masten BJ: Dendritic cells: immune regulators in health and disease. Physiol Rev 82: 97-130, 2002.
18. Steinman RM, Hawiger D and Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711, 2003.
19. Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, Chu FF, Randolph GJ, Rudensky AY and Nussenzweig M: In vivo analysis of dendritic cell development and homeostasis. Science 324: 392-397, 2009.
20. Conti L, Cardone M, Varano B, Puddu P, Belardelli F and Gessani S: Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol 38: 750-762, 2008.
21. Conti L and Gessani S: GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology 213: 859-870, 2008.
22. Shortman K and Naik SH: Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7: 19-30, 2007.
23. Niessner A and Weyand CM: Dendritic cells in atherosclerotic disease. Clin Immunol 134: 25-32, 2009
24. Buckwalter MR and Albert ML: Orchestration of the immune response by dendritic cells. Curr Biol 19: R355-R361, 2009.
25. Segura E and Villadangos JA: Antigen presentation by dendritic cells in vivo. Curr Opin Immunol 21: 105-110, 2009.
26. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ and Weyand CM: Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 114: 2482-2489, 2006. (Pubitemid 44901521)
27. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL and Weyand CM: Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 116: 2043-2052, 2007. (Pubitemid 350023750)
28. Loskog A, Ninalga C and Tötterman TH: Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer Immunol Immunother 55: 588-597, 2006.
29. Kobayashi T, Walsh MC and Choi Y: The role of TRAF6 in signal transduction and the immune response. Microbes Infect 6: 1333-1338, 2004. (Pubitemid 39539732)
30. Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ and Lutgens E: The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 102: 206-214, 2009.
31. Beckman EM and Brenner MB: MHC class I-like, class II-like and CD1 molecules: distinct roles in immunity. Immunol Today 16: 349-352, 1995.
32. Carreno BM and Collins M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20: 29-53, 2002.
33. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ and Weyand CM: Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 199: 173-183, 2004. (Pubitemid 38129698)
34. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ and Weyand CM: Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118: 1276-1284, 2008.
35. Randolph GJ, Ochando J and Partida-Sánchez S: Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 26: 293-316, 2008. (Pubitemid 351600378)
36. Shimada K: Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 73: 994-1001, 2009.
37. Millonig G, Niederegger H, Rabl W, Hochleitner BW, Hoefer D, Romani N and Wick G: Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol 21: 503-508, 2001. (Pubitemid 32323380)
38. Bauriedel G, Jabs A, Skowasch D, Hutter R, Badimon JJ, Fuster V, Welsch U and Lüderitz B: Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression withanti-apoptotic Bcl-2 and HSP47 in arterial repair. J Am Coll Cardiol 42: 930-938, 2003. (Pubitemid 37059756)
39. Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, Raaz D, Anger T, Amann K, Probst T, Ludwig J, Daniel WG and Garlichs CD: Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 176: 101-110, 2004.
40. Kawahara I, Kitagawa N, Tsutsumi K, Nagata I, Hayashi T and Koji T: The expression of vascular dendritic cells in human atherosclerotic carotid plaques. Hum Pathol 38: 1378-1385, 2007. (Pubitemid 47247481)
41. Skowasch D, Jabs A, Andrié R, Dinkelbach S, Lüderitz B and Bauriedel G: Presence of bone-marrow- and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis. Cardiovasc Res 60: 684-691, 2003. (Pubitemid 37501126)
42. Bobryshev YV, Lord RS and Pärsson H: Immunophenotypic analysis of the aortic aneurysm wall suggests that vascular dendritic cells are involved in immune responses. Cardiovasc Surg 6: 240-249, 1998.
43. Yilmaz A, Schaller T, Cicha I, Altendorf R, Stumpf C, Klinghammer L, Ludwig J, Daniel WG and Garlichs CD: Predictive value of the decrease in circulating dendritic cell precursors in stable coronary artery disease. Clin Sci 116: 353-363, 2009.
44. Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, Ginhoux F, Miller ER, Witztum JL, Chapman MJ and Lesnik P: Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation 119: 2367-2375, 2009.
45. Merad M and Manz MG: Dendritic cell homeostasis. Blood 113: 3418-3427, 2009.
46. Bachetoni A, D'Ambrosio A, Mariani P, Cortesini R and Quintieri F: Diltiazem impairs maturation and functions of human dendritic cells. Hum Immunol 63: 524-533, 2002. (Pubitemid 34686431)
47. Luo Y, Liang C, Xu C, Jia Q, Huang D, Chen L, Wang K, Wu Z and Ge J: Ciglitazone inhibits oxidized-low density lipoprotein induced immune maturation of dendritic cells. J Cardiovasc Pharmacol 44: 381-385, 2004. (Pubitemid 39129458)
48. Shi HY, Ge JB, Fang WY, Yao K, Sun AJ, Huang RC, Jia QZ, Wang KQ, Zou YZ and Cao XT: Peroxisome proliferator-activated receptor alpha agonist attenuates oxidized-low density lipoprotein induced immune maturation of human monocyte-derived dendritic cells. Chin Med J 121: 1747-1750, 2008.
49. Kwak B, Mulhaupt F, Myit S and Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402, 2000. (Pubitemid 32001026)
50. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R and Zipp F: Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197: 725-733, 2003. (Pubitemid 36350867)
51. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L and Zamvil SS: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84, 2002.
52. Yilmaz A, Reiss C, Weng A, Cicha I, Stumpf C, Steinkasserer A, Daniel WG and Garlichs CD: Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 79: 529-538, 2006. (Pubitemid 44831230)
53. Kofler S, Schlichting C, Jankl S, Nickel T and Weis M: Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion. Atherosclerosis 197: 105-110, 2008. (Pubitemid 351284479)
54. Skaletz-Rorowski A, Lutchman M, Kureishi Y, Lefer DJ, Faust JR and Walsh K: HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc Res 57: 253-264, 2003. (Pubitemid 36009458)
55. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ, Kemp BE and Venema RC: Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287: H560-H566, 2004.
56. Kajimoto K, Miyauchi K, Kasai T, Shimada K, Kojima Y, Shimada A, Niinami H, Amano A and Daida H: Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 206: 505-511, 2009.